Melanoma Recurrence and Spread Are Reduced by The Moderna, Merck Vaccine, Providing Fresh Hope for Treatment

A personalized mRNA cancer vaccine decreased the risk of recurrence and spread of melanoma in a late-stage trial, according to Moderna (MRNA.O), opens new tab, and Merck (MRK.N), opens new tab. This significant achievement in a novel area of cancer treatment caused Moderna’s stock to rise as much as 160%.

The vaccination was studied in conjunction with Merck’s immunotherapy medication Keytruda, a popular treatment for melanoma. In an interview, Moderna President Stephen Hoge stated that if authorities approve the vaccination, thousands of patients who have had surgery to remove high-risk melanoma tumors might start receiving benefits as early as next year.

This is the first successful late-stage trial outcome for an mRNA cancer vaccine, which teaches a patient’s immune system to combat tumors by focusing on particular mutations in those cells. It is also the first study of its kind to demonstrate that supplementing Keytruda with a treatment was more effective than using it alone. Similar strategies are being tested by Merck, Moderna, and other businesses against pancreatic, breast, and lung cancers.

The Moderna results may herald a new era in the treatment of solid-tumor tumors, according to Karen Knudsen, CEO of the Parker Institute for Cancer Immunotherapy.

Knudsen stated, “The positive hit here leads us…into this next phase in immunotherapy.” “This is an auspicious start — this is where things begin.”

The findings marked a turnabout for Moderna, which has had difficulty developing new products outside of its COVID-19 vaccine and encountered opposition from President Donald Trump’s administration on its mRNA technology. Robert F. Kennedy Jr., the U.S. Secretary of Health and Human Services, has slashed $500 million from mRNA vaccine studies and questioned the efficacy and safety of these vaccinations.